KRS Capital Management’s Rockwell Medical RMTI Stock Holding History

KRS Capital Management’s Portfolio RMTI Stock Details RMTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3	Closed	–	–	303
2021 Q4	$0	Buy	+3	New	+$161	﹤0.01%	395

Other funds holding RMTI

Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCA

Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SkyOak Wealth Southfield, Michigan $546M AUM 18.14% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

KRS Capital Management's RMTI Position: Q1 2022 in Review

KRS Capital Management sold out of Rockwell Medical (RMTI) in Q1 2022, closing a stake of 3 shares.

KRS Capital Management first reported a position in RMTI in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 58 funds tracked by Wall St. Rank hold RMTI as of Q1 2022.

KRS Capital Management reported no remaining Rockwell Medical position as of Q1 2022 after selling out during the quarter.
KRS Capital Management sold 3 Rockwell Medical shares in Q1 2022.
KRS Capital Management first reported a position in Rockwell Medical in Q4 2021 and held it in 1 quarter.
KRS Capital Management's Rockwell Medical position peaked at $0 in Q4 2021.
58 funds tracked by Wall St. Rank held Rockwell Medical as of Q1 2022.

Based on KRS Capital Management's 13F filing for Q1 2022, filed 27 Apr 2022.